Gisela Mir Arnau

Vall d'Hebron Institut de Recerca — Spain

Biochemistry, Genetics and Molecular Biology · Life Sciences

45h-index18.6kcitations161works9.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(44), Acute Myeloid Leukemia Research(25), Immune cells in cancer(25), Ovarian cancer diagnosis and treatment(22), Cytokine Signaling Pathways and Interactions(20)

Publications114 total

Abstract B018: Impact of 13q.14 loss in prostate cancer progression and sensitivity to targeted agents
Cancer Research·2026
Abstract PR029: Monitoring tumor evolution and phenotypic diversity in metastatic prostate cancer using liquid biopsy profiling
Cancer Research·2026
Abstract 304: Profiling the acute effects of androgen receptor inhibition in hormone-sensitive prostate cancer
Cancer Research·2025· 1 cited
Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence
Cell Reports Medicine·2025· 7 citedOpen Access
RNA kinetics influence the response to transcriptional perturbation in leukaemia cell lines
NAR Cancer·2024· 2 citedOpen Access
Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution
Cancer Cell·2024· 55 citedOpen Access
Evaluation of homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional tissue-based immunofluorescence assays
2024· 1 citedOpen Access
Supplementary Table from Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML
2023Open Access
Supplementary Table from Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML
2023Open Access
Supplementary Table from Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML
2023Open Access
Supplementary Table from Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML
2023Open Access
Supplementary Figure from Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML
2023Open Access
Supplementary Table from Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML
2023Open Access
Supplementary Table from Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML
2023Open Access
Supplementary Table from Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML
2023Open Access
Supplementary Table from Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML
2023Open Access
Data from Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML
2023Open Access
Supplementary Table from Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML
2023Open Access
Supplementary Table from Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML
2023Open Access
Data from Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Timothy Semple(20), David D.L. Bowtell(15), Jason Li(12), Ricky W. Johnstone(10), Anthony T. Papenfuss(10), Dale W. Garsed(9), Sián Fereday(9), Kathryn Alsop(9), Joy Hendley(9), Elizabeth L. Christie(8), Dariush Etemadmoghadam(8), Michael Friedländer(8), Mark Shackleton(8), Stephen Q. Wong(8), Stephen B. Fox(8), Sreeja Gadipally(8), Joshy George(6), Anne Hamilton(6), Linda Mileshkin(6), Catherine J. Kennedy(6)